Sanofi explores combination treatments for multiple myeloma in new late-stage trials
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma. December 07, 2017